Sustained Hair Regrowth With Ritlecitinib to Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

    March 2023 in “ SKIN The Journal of Cutaneous Medicine ”
    Melissa Piliang, Charles Lynde, Brett King … Liza Takiya
    Studysummary This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jofskin.org →
    Discuss this study in the Community →

    Related research 4

    1. Sustained Hair Regrowth With Ritlecitinib to Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study SKIN The Journal of Cutaneous Medicine · 2023
    2. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    3. Linear Alopecia Areata JAAD case reports · 2018
    4. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018